Large gap with delayed quotes
Analysis date: 13.10.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 14.04.2026.
Quality
Strong
Strong
Three stars since 11.08.2026.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 07.11.2025 at a price of 3.91.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 07.08.2026.
4wk Rel Perf
13.86%
13.86%
The four-week dividend-adjusted overperformance versus SP500 is 13.86%.
Risk
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.84%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.70%.
Mkt Cap in $bn
4.09
4.09
With a market capitalization between $2 & $8bn, ABCELLERA BIOLOGICS is considered a mid-cap stock.
G/PE Ratio
-0.58
-0.58
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-25
-25
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-14.55%
-14.55%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
210
210
For 1% of index variation, the stock varies on average by 2.10%.
Correlation
0.27
0.27
Stock movements are strongly independent of index variations.
Value at Risk
9.66
9.66
The value at risk is estimated at USD 9.66. The risk is therefore 76.58%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
26.03.2021
26.03.2021